trending Market Intelligence /marketintelligence/en/news-insights/trending/qunsejnqiqymvwxavqze0q2 content esgSubNav
In This List

CVS Pharmacy offers GlaxoSmithKline's shingles vaccine

Blog

Using ESG Analysis to Support a Sustainable Future

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings


CVS Pharmacy offers GlaxoSmithKline's shingles vaccine

CVS Health Corp. on March 16 began offering GlaxoSmithKline PLC's new Shingrix shingles vaccine at all CVS Pharmacy locations in the U.S.

The move follows the licensing of the vaccine by the U.S. Food and Drug Administration in 2017 and its recommendation by the Centers for Disease Control and Prevention.

The Rhode Island-based drug retailer said healthy adults aged 50 and up are recommended to get two doses of the vaccine, two to six months apart, with 99% of people in the age category at risk of getting shingles in their lifetime.